

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Hepalink**

**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**  
**(深圳市海普瑞藥業集團股份有限公司)**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock code: 9989)**

**ANNOUNCEMENT**

**PROPOSED AMENDMENTS TO THE ARTICLES**

This announcement is issued by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (**Company**), which is listed on the Shanghai Stock Exchange Limited (the **Stock Exchange**) (the **Listing Rules**).

The Company has issued the 2023 Financial and General Meeting, Agenda and Call Notice and HS Agenda and Call Notice on December 15, 2023, and the agenda and call notice of the Annual General Meeting of the Company (the **Articles**). The agenda and call notice of the Annual General Meeting of the Company, the agenda and call notice of the HS Agenda and Call Notice, and the agenda and call notice of the Annual General Meeting of the Company.

The Board of Directors (the **Board**) of the Company and the Company's Shareholders, and the **Proposed Amendments to the Articles**.

On February 14, 2023, the State Council (the **State Council**) of the PRC (the **PRC**) issued the Decision of the State Council on the Abolition of Part of Administrative Regulations and Documents (the **Decision**), which cancelled the abrogation of the State Regulations and the Order of the Office and Letter of the State Administration Commission (the **State Administration Commission**) on the Special Regulations for Overseas Share Issuance and Listing of Joint Stock Limited Companies (the **Special Regulations**) issued by the State Council on April 4, 1994. On February 17, 2023, the China Securities Regulatory Commission (the **CSRC**) issued the Trial Measures for Overseas Share Issuance and Listing of Domestic Enterprises (the **Trial Measures**) and the related rules, which cancelled the abrogation of the Notice of

Implementation of Mandatory Provisions of Company Law of the PRC on Overseas-listed Companies (《關於執行到境外上市公司章程必備條款的通知》). The Company and the Company are subject to the provisions of the New PRC Regulations) as of the effective date of the Company's listing on the Main Board of the Shanghai Stock Exchange on March 31, 2023.